Data From Genzyme Corporation’s Multiple Sclerosis Franchise Featured At American Academy of Neurology

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that 18 poster and oral presentations featuring Aubagio® (teriflunomide) and LemtradaTM (alemtuzumab) will be presented during the 66th American Academy of Neurology (AAN) Annual Meeting to be held in Philadelphia, April 26 – May 3, 2014.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC